Answers are grounded in this paper and cite their sources.
This study investigated the dosimetric, hematologic toxicity (HT), and clinical efficacy benefits of pelvic bone marrow-sparing volumetric modulated arc therapy (PBMS-VMAT) in cervical cancer patients undergoing concurrent chemoradiotherapy (CCRT). Between October 2023 and March 2024, 244 cervical cancer patients undergoing CCRT were enrolled and classified into the PBMS-VMAT group or the control group. The PBMS-VMAT group received additional pelvic bone marrow (BM) dose-volume constraints. Dosimetric parameters, acute HT, and preliminary clinical efficacy were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for grade 2 or higher (G2 + ) HT. Dynamic changes in lymphocyte counts were also evaluated. There were no statistically significant differences in target-volume dosimetric parameters between the two groups. However, PBMS-VMAT significantly reduced pelvic BM V 10 , V 20 , and V 40 values, while no significant differences were observed in bladder, rectum, bowel, or femoral head dosimetry. G2 + HT was significantly lower in the PBMS-VMAT group (51.6% vs. 73.0%; 95% CI : − 37.8% to − 4.0%; P = 0.014), and lymphocyte counts were higher during and after CCRT. The complete response rate was 61.48% in the PBMS-VMAT group versus 48.36% in the control group (95% CI : 0.86%–24.38%; P = 0.04). Among all variables examined, V 10 remained the only factor independently associated with HT (odds ratio 1.16; 95% CI : 1.07–1.26; P < 0.001). PBMS-VMAT not only limits acute radiation-induced lymphopenia but also shortens the recovery window. In cervical cancer patients undergoing CCRT, PBMS-VMAT effectively protects bone marrow hematopoietic function while maintaining target dose coverage and satisfying organ-at-risk dose constraints. Thus, PBMS-VMAT may represent a superior radiotherapy technique for CCRT in cervical cancer and holds promise for broader clinical application.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: